Potential for Developing New Drugs Against Mycobacterial Infections

This review examines the development of new antimycobacterial drugs, including fluoroquinolones and macrolides.

• Fluoroquinolones such as ciprofloxacin and levofloxacin show activity against Mycobacterium tuberculosis and Mycobacterium avium complex.
• New macrolides, including clarithromycin and azithromycin, are also evaluated for their effectiveness against these mycobacterial species.
• Rifamycin derivatives like rifabutin and rifapentine are part of the assessment for their in-vitro and in-vivo activities.
• The review includes a brief discussion on the therapeutic efficacy of these drugs in clinical treatment.

Simplified